Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia
Alisa B. Lee‐Sherick(The Medical Center of Aurora), Douglas K. Graham(Emory University)
Cited by 105
Related Papers
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia
|JCI Insight|2016|78
Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia
|Blood Cancer Journal|2013|57